Efficacy of TRAIL treatment against HPV16 infected cervical cancer cells undergoing senescence following siRNA knockdown of E6/E7 genes

Biochemical and Biophysical Research Communications

Volumn 405, Issue 1, 2011, Pages 1-6

  Eaton, Seron ^a   Wiktor, Peter ^a   Thirstrup, Derek ^b   Lake, Douglas ^c   Nagaraj, Vinay Janthakahalli ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Combinatorial cancer treatment; Drug resistant cervical cancer; Senescence; SiRNA therapy; Tumor necrosis factor related apoptosis inducing ligand (TRAIL)

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA GALACTOSIDASE; DEATH RECEPTOR 4; DEATH RECEPTOR 5; PROTEIN E6; PROTEIN E7; PROTEIN P53; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL AGING; CELL CYCLE; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; UTERINE CERVIX CANCER;

CELL AGING; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMAN PAPILLOMAVIRUS 16; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 79551496194     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.12.056     Document Type: Article

References (34)

1. Yugawa T., Kiyono T. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Reviews in Medical Virology 2009, 19:97-113.
2. CDC, Gynecological Cancers: Cervical Cancer Statistics, 2010. Available from: http://www.cdc.gov/cancer/cervical/statistics/.
3. Clifford G.M., Smith J.S., Plummer M., Munoz N., Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. British Journal of Cancer 2003, 88:63-73.
4. Bosch F.X., de Sanjose S. Chapter 1: human papillomavirus and cervical cancer-burden and assessment of causality. Journal of the National Cancer Institute Monographs 2003, 3-13.
5. Alba A.M.C.a.C.R.-C. The Human papillomavirus (HPV) in human pathology: description, pathogenesis, oncogenic role, epidemiology and detection techniques. The Open Dermatology Journal 2009, 3:90-102.
6. zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology 2009, 384:260-265.
7. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., Schiffman M.H., Moreno V., Kurman R., Shah K.V., Alihonou E., Bayo S., Mokhtar H.C., Chicareon S., Daudt A., Delosrios E., Ghadirian P., Kitinya J.N., Koulibaly M., Ngelangel C., Tintore L.M.P., Riosdalenz J.L., Sarjadi, Schneider A., Tafur L., Teyssie A.R., Rolon P.A., Torroella M., Tapia A.V., Wabinga H.R., Zatonski W., Sylla B., Vizcaino P., Magnin D., Kaldor J., Greer C., Wheeler C. Prevalence of human papillomavirus in cervical-cancer - a worldwide perspective. Journal of the National Cancer Institute 1995, 87:796-802.
8. Govan V.A. A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil). Therapeutics and Clinical Risk Management 2008, 4:65-70.
9. Franco E.L., Schlecht N.F., Saslow D. The Epidemiology of Cervical Cancer. The Cancer Journal 2003, 9:348-359.
10. Thomison Iii J., Thomas L.K., Shroyer K.R. Human papillomavirus: molecular and cytologic/histologic aspects related to cervical intraepithelial neoplasia and carcinoma. Human Pathology 2008, 39:154-166.
11. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. Journal of the National Cancer Institute 2000, 92:690-698.
12. Hannon G.J. RNA interference. Nature 2002, 418:244-251.
13. Horner S.M., DeFilippis R.A., Manuelidis L., DiMaio D. Repression of the human papillomavirus E6 gene initiates p53-dependent, telomerase-independent senescence and apoptosis in HeLa cervical carcinoma cells. Journal of Virology 2004, 78:4063-4073.
14. Tang S., Tao M., McCoy J., Zheng Z.M. Short-term induction and long-term suppression of HPV16 oncogene silencing by RNA interference in cervical cancer cells. Oncogene 2006, 25:2094-2104.
15. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A., Goodwin R.G. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682.
16. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. Journal of Biological Chemistry 1996, 271:12687-12690.
17. de Vries E.G., Gietema J.A., de Jong S. Tumor necrosis factor-related apoptosis-inducing ligand pathway and its therapeutic implications. Clinical Cancer Research 2006, 12:2390-2393.
18. Kimberley F.C., Screaton G.R. Following a TRAIL: update on a ligand and its five receptors. Cell Research 2004, 14:359-372.
19. Almasan A., Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine and Growth Factor Reviews 2003, 14:337-348.
20. Falschlehner C., Emmerich C.H., Gerlach B., Walczak H. TRAIL signalling: decisions between life and death. International Journal of Biochemistry and Cell Biology 2007, 39:1462-1475.
21. Wajant H., Pfizenmaier K., Scheurich P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 2002, 7:449-459.
22. Reesink-Peters N., Hougardy B.M.T., Van den Heuvel F.A.J., ten Hoor K.A., Hollema H., Boezen H.M., de Vries E.G.E., de Jong S., van der Zee A.G.J. Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecologic Oncology 2005, 96:705-713.
23. Hougardy B.M.T., Maduro J.H., Zee A.G.J.v.d., Groot D.J.A.d., Heuvel F.A.J.v.d., Vries E.G.E.d., Jong S.d. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. International Journal of Cancer 2006, 118:1892-1900.
24. Ui-Tei K., Naito Y., Takahashi F., Haraguchi T., Ohki-Hamazaki H., Juni A., Ueda R., Saigo K. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Research 2004, 32:936-948.
25. Naito Y., Yamada T., Ui-Tei K., Morishita S., Saigo K. SiDirect: highly effective, target-specific siRNA design software for mammalian RNA interference. Nucleic Acids Research 2004, 32:W124-129.
26. Yamato K., Yamada T., Kizaki M., Ui-Tei K., Natori Y., Fujino M., Nishihara T., Ikeda Y., Nasu Y., Saigo K., Yoshinouchi M. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer. Cancer Gene Therapy 2008, 15:140-153.
27. Liu X., Yue P., Khuri F.R., Sun S.Y. P53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Research 2004, 64:5078-5083.
28. Sheikh M.S., Burns T.F., Huang Y., Wu G.S., Amundson S., Brooks K.S., Fornace A.J., el-Deiry W.S. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Research 1998, 58:1593-1598.
29. Gosselin K., Deruy E., Martien S., Vercamer C., Bouali F., Dujardin T., Slomianny C., Houel-Renault L., Chelli F., De Launoit Y., Abbadie C. Senescent keratinocytes die by autophagic programmed cell death. American Journal of Pathology 2009, 174:423-435.
30. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., Pereira-Smith O., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:9363-9367.
31. Wang X., Wong Y.C. Induction of tumour cell senescence. a new strategy in anticancer treatment. Medicinal Chemistry Reviews-Online 2004, 1:369-379.
32. Edinger A.L., Thompson C.B. Death by design: apoptosis, necrosis and autophagy. Current Opinion in Cell Biology 2004, 16:663-669.
33. Wang P., Zhang J., Bellail A., Jiang W., Hugh J., Kneteman N.M., Hao C. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cellular Signalling 2007, 19:2237-2246.
34. Chuang S.-E., Yeh P.-Y., Lu Y.-S., Lai G.-M., Liao C.-M., Gao M., Cheng A.-L. Basal levels and patterns of anticancer drug-induced activation of nuclear factor-[kappa]B (NF-[kappa]B), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochemical Pharmacology 2002, 63:1709-1716.